Pfizer
PFE
$26.92
-1.10%
Pfizer Inc. is one of the world's largest pharmaceutical firms, primarily engaged in the discovery, development, and commercialization of prescription drugs and vaccines. The company is a global leader in the drug manufacturing industry, with a diversified portfolio anchored by blockbuster products like the pneumococcal vaccine Prevnar 13, cardiovascular drug Eliquis, and Vyndaqel for cardiomyopathy. The current investor narrative is dominated by the company's post-COVID revenue normalization and strategic pivot to reignite growth, as evidenced by recent pipeline developments like a major win in a prostate cancer trial for its Talzenna/Xtandi combo, alongside navigating significant regulatory and competitive headwinds, including potential 100% tariffs on imported drugs which could reshape the competitive landscape.…
PFE
Pfizer
$26.92
Related headlines
Investment Opinion: Should I buy PFE Today?
Rating & Thesis: Hold. Pfizer presents a classic 'value trap' scenario—its seemingly cheap forward P/E of 9.56x and high 6.9% yield are attractive, but they are counterbalanced by significant earnings volatility and a lack of clear organic growth catalysts, making a Buy recommendation premature despite recent analyst upgrades.
Supporting Evidence: The valuation argument is compelling on the surface: a forward P/E of 9.56x is a deep discount to its own trailing multiple of 18.2x and likely to the broader biopharma sector. The company's strong $9.08B TTM free cash flow and manageable 0.78 debt-to-equity ratio provide financial resilience. However, operational metrics are weak, with Q4 revenue declining 1.16% YoY and the company posting a substantial net loss, highlighting the core challenge. Furthermore, the implied price target from consensus EPS and the forward P/E is ~$21.04, suggesting -21.8% downside from current levels.
Risks & Conditions: The two biggest risks are continued earnings volatility preventing a re-rating, and the failure of pipeline catalysts like the prostate cancer combo to materially offset post-COVID declines. This Hold would upgrade to a Buy if the forward P/E compresses further alongside demonstrable quarterly revenue and earnings growth (e.g., two consecutive quarters of >5% organic revenue growth and positive net income). It would downgrade to a Sell if the stock breaks above $29 without fundamental improvement or if TTM free cash flow falls significantly, threatening the dividend. The stock appears fairly valued to slightly overvalued relative to its near-term earnings power, as the market seems to be pricing in a recovery that is not yet evident in the financials.
Sign up to view all
PFE 12-Month Price Forecast
The AI assessment is neutral based on conflicting signals: compelling valuation and income metrics are offset by weak and volatile fundamentals. The high implied downside to analyst targets is a major concern, suggesting the recent rally may be overdone. Confidence is medium because the outcome heavily depends on binary events like tariff decisions and pipeline commercialization, which are difficult to model. The stance would upgrade to bullish on confirmation of sustained quarterly profit growth and a successful pipeline launch, or downgrade to bearish on a breakdown below the $24 support level on high volume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $35.00 and implied upside of +30.0% versus the current price.
Average Target
$35.00
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$22 - $35
Analyst target range
Pfizer is covered by 11 analysts, indicating substantial institutional interest. The consensus sentiment appears mixed but leans cautiously optimistic, with recent actions including Guggenheim and HSBC maintaining 'Buy' ratings and Argus Research upgrading from 'Hold' to 'Buy' in early March 2026. The average target price implied by the estimated EPS consensus of $2.20 and a forward PE of 9.56x suggests a price target of approximately $21.04, which would imply a -21.8% downside from the current price of $26.92; however, this calculation uses the forward PE as a proxy, and the actual consensus price target is not explicitly provided in the data. The target range derived from estimated EPS shows a low of $2.11 and a high of $2.28, translating to a price range of roughly $20.18 to $21.80 using the forward PE, signaling a relatively tight band of expectations and moderate uncertainty among analysts regarding the company's near-term earnings power. The recent news flow regarding pipeline successes and tariff exemptions could be catalysts that push the stock toward the higher end of expectations, while the wide gap between trailing and forward PE underscores the market's expectation for a significant earnings rebound that is not yet fully realized in the share price.
Bulls vs Bears: PFE Investment Factors
The evidence presents a complex and balanced picture for Pfizer. The bull case is anchored in a compelling valuation (9.56x forward P/E), a fortress balance sheet with strong cash flow supporting a 6.9% yield, and recent pipeline successes that could reignite growth. The bear case focuses on severe earnings volatility, a lack of clear post-COVID revenue growth, and analyst models that imply significant downside from current levels. Currently, the bearish arguments on earnings fundamentals and valuation appear to have stronger evidence, as the stock's recent 24.7% rally seems to have outpaced the still-challenging operational reality. The single most important tension in the investment debate is whether the company's forward P/E of 9.56x represents a deep-value opportunity or a justified discount for a business struggling to demonstrate consistent, profitable growth beyond its pandemic peak.
Bullish
- Strong Cash Flow & Dividend Yield: Pfizer generated $9.08 billion in trailing twelve-month free cash flow, providing a robust foundation for its business. This supports its generous 6.9% dividend yield, making it attractive for income-focused investors and signaling financial stability.
- Attractive Forward Valuation: The stock trades at a forward P/E of 9.56x, which is significantly below its trailing P/E of 18.2x. This steep discount reflects market pessimism and offers a substantial margin of safety if earnings recover as analysts project with an estimated EPS of $2.20.
- Pipeline Success & Strategic Pivot: Recent positive Phase 3 data for the Talzenna/Xtandi prostate cancer combo provides a clear near-term growth catalyst. This success demonstrates the company's ability to execute its strategic pivot to reignite growth beyond its post-COVID revenue normalization.
- Defensive Profile & Technical Recovery: With a beta of 0.388, Pfizer has been 61% less volatile than the market, offering defensive characteristics. The stock is up 24.69% over the past year and is trading at 84% of its 52-week range, indicating a sustained recovery trend from its lows.
Bearish
- Earnings Volatility & Q4 Loss: The company swung to a significant Q4 2025 net loss of -$1.65 billion (net margin -9.4%), contrasting sharply with a $3.54 billion profit in Q3. This extreme quarterly volatility in profitability creates uncertainty and complicates earnings forecasting.
- Post-COVID Revenue Normalization: Q4 2025 revenue of $17.56B declined 1.16% year-over-year, following a volatile quarterly pattern. The lack of a clear organic growth trend as COVID-related windfalls subside remains a core challenge for the investment thesis.
- Analyst Targets Suggest Downside: Using the consensus EPS estimate of $2.20 and the forward P/E of 9.56x implies a price target of ~$21.04. This represents a potential 21.8% downside from the current price of $26.92, indicating the market may have run ahead of fundamentals.
- High Payout Ratio & Margin Pressure: The trailing twelve-month payout ratio is 125.8%, meaning the dividend is not fully covered by earnings. While supported by strong cash flow, this highlights underlying earnings pressure, with Q4 gross margin dipping to 70.0% from 70.3% TTM.
PFE Technical Analysis
Pfizer's stock is in a sustained recovery trend from its 52-week lows, with a 1-year price change of +24.69%, significantly outperforming its own recent history. The current price of $26.92 positions it at approximately 84% of its 52-week range ($21.28 to $28.75), indicating it is trading closer to the upper bound of its yearly range, which suggests recovering investor confidence but also proximity to a key technical resistance level. The stock has demonstrated positive momentum over the medium term, with a 3-month gain of 5.65% and a 6-month gain of 8.64%, though it has pulled back 1.39% over the past month, suggesting a potential consolidation or profit-taking phase after its recent run-up. This recent 1-month dip contrasts with the strong yearly performance, possibly signaling a pause as the stock approaches its 52-week high resistance, with a beta of 0.388 indicating it has been significantly less volatile than the broader market (SPY) during this period. Key technical support is anchored at the 52-week low of $21.28, while immediate resistance sits near the 52-week high of $28.75; a decisive breakout above $28.75 could signal a continuation of the bullish recovery trend, while a failure and reversal could see a test of lower support levels. The stock's low beta of 0.388 implies it has been a defensive holding, moving with only 39% of the market's volatility, which is a critical consideration for risk-averse investors seeking stability within the healthcare sector.
Beta
0.39
0.39x market volatility
Max Drawdown
-19.0%
Largest decline past year
52-Week Range
$22-$29
Price range past year
Annual Return
+24.7%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | -1.4% | +2.6% |
| 3m | +5.7% | -2.3% |
| 6m | +8.6% | +2.6% |
| 1y | +24.7% | +27.3% |
| ytd | +6.9% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Pfizer's revenue trajectory reflects the challenging post-pandemic normalization, with Q4 2025 revenue of $17.56 billion representing a year-over-year decline of 1.16%. This follows a volatile quarterly pattern, where revenue dipped from $17.76B in Q4 2024 to $13.72B in Q1 2025, before recovering to $16.65B in Q3 2025, indicating ongoing volatility rather than a clear growth trend as the company moves past its COVID-related windfall. Profitability has been inconsistent, with the company swinging to a significant net loss of -$1.65 billion in Q4 2025 (net margin of -9.4%), contrasting sharply with a net income of $3.54 billion in Q3 2025; however, the trailing twelve-month picture shows a net margin of 12.4% and a gross margin of 70.3%, highlighting that underlying core profitability remains robust despite quarterly noise from one-time charges or write-offs. The balance sheet and cash flow position remain a key strength, with a manageable debt-to-equity ratio of 0.78 and a current ratio of 1.16 providing adequate liquidity, while the company generated substantial trailing twelve-month free cash flow of $9.08 billion, which supports its generous dividend yield of 6.9% and provides internal funding for business development and R&D investments.
Quarterly Revenue
$17.6B
2025-12
Revenue YoY Growth
-0.01%
YoY Comparison
Gross Margin
+0.69%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Given the company's positive trailing net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Pfizer's trailing PE ratio stands at 18.2x, while its forward PE is significantly lower at 9.56x, indicating the market anticipates a substantial recovery in earnings over the next twelve months. Compared to the broader Drug Manufacturers industry, Pfizer's trailing PE of 18.2x is likely at a discount to many high-growth biopharma peers, though its forward multiple of 9.56x suggests the market is pricing in a more mature, value-oriented profile with moderate growth expectations. Historically, the stock's own valuation has compressed significantly from pandemic-era highs; the current trailing PE of 18.2x is well below the elevated multiples seen in 2021-2022 (e.g., 24.4x in Q4 2021) and is more in line with its longer-term historical average, suggesting the stock is not overextended and may offer value if earnings stabilize and grow as projected.
PE
18.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~1666x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Pfizer's primary financial risk is earnings volatility, as evidenced by the swing from a $3.54B net income in Q3 2025 to a -$1.65B loss in Q4. This inconsistency, driven by one-time charges and post-COVID normalization, makes forecasting difficult. While the dividend is supported by strong $9.08B TTM free cash flow, the 125.8% payout ratio indicates it is not covered by current earnings, creating a dependency on non-operational cash sources. Revenue concentration is another concern, with key products like Prevnar 13, Eliquis, and Vyndaqel driving results, exposing the company to patent cliffs and competitive pressures in these specific therapeutic areas.
Market & Competitive Risks: The stock trades at a significant premium to implied analyst targets, suggesting a high risk of valuation compression if earnings do not meet the optimistic rebound priced into the forward multiple. Externally, the pharmaceutical sector faces intense regulatory scrutiny, with the threat of 100% tariffs on imported drugs reshaping the competitive landscape, though Pfizer may secure an exemption. The stock's low beta of 0.388 offers defensive characteristics but also implies it may underperform in strong bull markets, presenting a sector rotation risk if investors pivot away from defensive healthcare names toward more cyclical growth.
Worst-Case Scenario: The most damaging scenario would involve a failure of key pipeline assets like the Talzenna/Xtandi combo to gain expected market traction, coupled with faster-than-anticipated erosion of mature blockbuster drugs like Eliquis from competition. This would be compounded by the company failing to secure a tariff exemption, imposing severe cost pressures on its international operations. Such a confluence could trigger multiple compression, driving the stock back toward its 52-week low of $21.28. From the current price of $26.92, this represents a realistic downside of approximately -21%, not accounting for potential dividend cuts if cash flow deteriorates.
FAQ
The key risks are, in order of severity: 1) Fundamental Volatility: Extreme quarterly earnings swings, like the Q4 2025 net loss of -$1.65B, create high uncertainty. 2) Growth Stagnation: The lack of clear organic revenue growth post-COVID, with Q4 revenue down 1.16% YoY, challenges the investment thesis. 3) Valuation Compression: The stock trades 21.8% above its implied analyst target, risking a sharp pullback if growth fails to materialize. 4) Regulatory & Competitive: Potential 100% tariffs on imported drugs and pipeline setbacks (e.g., Lyme vaccine trial stumble) pose external threats.
The 12-month forecast presents three scenarios with a 60% probability for a base case. The base case (60% probability) sees the stock trading between $23 and $26, as it grinds higher slowly, supported by its dividend but capped by muted growth. The bull case (25% probability) targets $28.75 to $32, driven by successful pipeline launches and tariff exemptions. The bear case (15% probability) risks a fall to the $21.28-$22.50 range, retesting the 52-week low on earnings misses and lost confidence. The most likely outcome is the base case, assuming the company meets consensus EPS estimates but fails to catalyze a significant multiple expansion.
PFE sends mixed valuation signals. Its forward P/E of 9.56x appears deeply undervalued compared to its own trailing P/E of 18.2x and likely to sector peers, suggesting the market prices in no growth. However, this discount is rationalized by a -1.16% YoY revenue decline in Q4 and extreme earnings volatility. Crucially, applying the forward P/E to the consensus EPS estimate of $2.20 yields a price of ~$21.04, which is 21.8% below the current price. This indicates the stock is overvalued relative to near-term earnings expectations, trading on hope for a recovery not yet in the numbers.
PFE is a complex buy at current levels. For income-focused, value investors with a long-term horizon, the 6.9% dividend yield and low forward P/E of 9.56x are attractive. However, the stock appears overvalued relative to analyst EPS targets, implying a 21.8% downside to ~$21.04. The biggest risk is that the cheap multiple reflects justified skepticism about the company's ability to return to consistent growth. It may be a good buy for those seeking high yield and who believe in the pipeline turnaround, but it carries significant fundamental and valuation risk in the near term.
PFE is primarily suitable for long-term investment. Its low beta of 0.388 and high 6.9% dividend yield are hallmarks of a long-term, defensive holding for income portfolios. The company's strategic pivot and pipeline development will take multiple quarters, if not years, to materially impact financials, making short-term trading highly speculative. Given the earnings volatility and transitional nature of the business, investors should have a minimum holding period of 2-3 years to allow the turnaround narrative to play out and to collect the substantial dividend while waiting.